



Foreword



"Lampang Cancer Hospital (LPCH), which is under the Department of Medical Services, Ministry of Public Health, provides cancer diagnosis and treatment services, including cancer registration, covering the northern region. The number of new cancer patients has been continuously increasing. Our hospital is committed to maintaining quality and service standards to ensure a good quality of life for cancer patients.

Currently, there are changes in social conditions and technology, as well as the outbreak of emerging diseases. LPCH has adjusted the hospital's strategic plan for the years 2023 to 2027, with a focus on the vision of becoming a high-performance cancer hospital in terms of technology and medical innovation, aiming to improve people's quality of life. The plan also includes a focus on academic development, knowledge transfer, and providing cancer care services through network partners.

In 2022, LPCH was certified in the Program and Disease-Specific Standard (PDSS) for "Caring for thyroid cancer patients after surgery," making it the first hospital in Thailand to receive this certification.

Furthermore, LPCH has been supporting the operations of Health Regions 1 and 2 in terms of academic support, treatment, and referrals for cancer patients in the northern region. As a result, the health regions have shown good performance. These successful outcomes are a result of the cooperation between the hospital's management team and personnel. LPCH continues to strive towards improving the quality of cancer care in all aspects, aiming to enhance the quality of life for all Thai people."

Weerawat

(Dr. Weerawat Ukranun)

Director of Lampang Cancer Hospital

Preface


The hospital-based cancer registration (HBCR) is a part of the cancer information system. The Ministry of Public Health has a policy for A, S, and M1-level hospitals to establish cancer registration and report HBCR as well. This policy has led to the development of a cancer registry and an annual report of cancer statistics in Thailand.

Lampang Cancer Hospital (LPCH) has an HBCR under the responsibility of the cancer registry unit, which started in 2000. The focus of the registry is on collecting quality data according to international standards, ensuring accuracy and reliability. In 2022, all staff members of the cancer registry unit at LPCH obtained a "Professional ICD-O Coding" certificate from Mahidol University in Thailand.

This cancer statistics annual report for 2022 is a report from the HBCR cancer registry. This HBCR report issue No. 23 presents the statistics of new cancer patients who received services at LPCH between January 1st and December 31st, 2022. The report provides an overview and separates the data by the five most common types of cancer.

The staff of the cancer registry unit would like to express their gratitude to the senior executive team for their ongoing support. They also extend their thanks to the staff of LPCH who have been involved in collecting cancer data. It is hoped that this annual report will be useful in planning the operation, support, and development of LPCH, as well as providing additional information to those who are interested.

Cancer registry staff
Lampang Cancer Hospital



Contents



Foreword	I
Preface	II
Faculty of providers	IV
Cancer diagnosis and treatment tools, Lampang Cancer Hospital	V
Process for Cancer Registry data collection	VII
Data visualization	VIII
Overview of new cancer patients in Lampang Cancer Hospital	1
10 Leading new cancer patients in Lampang Cancer Hospital by Sex	6
10 Leading new cancer patients in Lampang Cancer Hospital (Both Sex)	6
7 Common Cancers in Lampang Cancer Hospital	8
(1) Head and Neck Cancer	9
(2) Colorectal Cancer	12
(3) Liver and bile duct Cancer	15
(4) Trachea, Bronchus, and lung Cancer	18
(5) Breast Cancer	21
(6) Cervical Cancer	25
(7) Thyroid Cancer	29
Number of new cancer by age and sex in Lampang Cancer Hospital (Male)	32
Number of new cancer by age and sex in Lampang Cancer Hospital (Female)	33
Pathology according to site and sex	34
Productivity of Cancer Registry, Lampang Cancer Hospital	41
Refference	46

Functional structure Cancer registry unit, LPCH



Advisory group



Dr. Weerawat Ukranun
Director of Lampang Cancer Hospital



Dr. Tawarat Ruanrojrun
Deputy Director for Health System Development



Mrs. Sureerat Phuangsaikai
Deputy Director of Nursing



Dr. Peerawood Boonyanivas
Head of Digital Medical Department

Staff



Mrs. Karnchana Daoprasert
Registered Nurse
Head of cancer registry unit



Mrs. Arada Pawong
Medical Statistics Technician
Head of Medical Records and Statistics



Ms. Ratchaneewan Chansawang
Registered Nurse



Mrs. Kanniga Suksai
Registered Nurse



Ms. Sirinya Sangkam
Statistician



Ms. Monthitinun Praditkay
Statistician



Ms. Ketsiri Khamkhod
Statistician



Mrs. Panida Suwanamuang
General Service Officer



Contact:



<https://www.lpch.go.th/canreg/>



lampangregistry@gmail.com



054-335262-8 ต่อ 113



Cancer diagnosis and treatment tools, Lampang Cancer Hospital

Radiotherapy

- 2012, Intensity Modulated Radiation Therapy Treatment Planning (IMRT Planning).
- 2013, Quality Assurance and Intra Treatment Verification.
- 2013, Linear Accelerator with Multi-Leaf Collimator (started using January 2014).
- 2016, Three Dimension for Intensity Moderated Radiotherapy Treatment Planning and Atlas-Based Organ Delineation lesion drawing program.
- 2017, The device determines the position and shape of the lesion and adjacent normal organs with a program to analyze changes in lesion size and normal organs between radiation therapy.
- 2017, High Energy Linear Accelerator with six degrees of freedom couch for SBRT and radiation oncology information system.
- 2018, Patient QA for Pre-Treatment QA.
- 2019, High Dose rate Control after loading with cobalt-60; 25 channel.
- 2019, High Energy Linear Accelerator with Image Guide.
- 2022, Superficial Hyperthermia.



Volumetric Modulated
Arc therapy (VMAT)



Intensity Modulated Radiotherapy
Linear Accelerator

Diagnostic Radiology

- 2010, Aplio MX Ultrasound
- 2011, Aplio XG Ultrasound
- 2013, Digital Subtraction/Flat Panel Detector; Model ZEXIRA
- 2016, Digital General x-ray
- 2016, Digital Mobile X-ray; Model SM-20HF-B-D-C
- 2018, Selenia Dimensions Digital Mammogram 2D and 3D
- 2019, Aplio i600 Ultrasound
- 2021, LOGIQ E10 Ultrasound
- 2021, Picture Archiving and Communication System and Radiology Information System (PACS & RIS)
- 2022, Aquilion Prime SP 160 Slice CT scanner

Nuclear Medicine


- 2011, Single Photon Emission Computed Tomography; SPECT
- 2013, CT Scan 16 Slice for use with SPECT
- 2016, Bone densitometer
- 2017, Thyroid uptake
- 2018, Single Photon Emission Computed Tomography/CT; SPECT/CT




Single Photon Emission Computed Tomography/CT; SPECT/CT




Process for Hospital-Based Cancer Registry data collection



Hospital-Based Cancer




Male



1. Colorectal
2. Prostate
3. Lung
4. Oral cavity and Larynx
5. Liver and bile duct

Female




1. Breast
2. Cervix uteri
3. Colorectal
4. Lung
5. Thyroid

Cancer Registry 2022

1

90%

of the patients live in health region 1



2

7%

of the patients live in health region 2



Type of Diagnosis

94% Histological proof

- ✓ Histology of primary
- ✓ Histology of metastasis
- ✓ Cytology and hematology

6% No histological proof

- ✓ Clinical investigation
- ✓ Surgery without histology




Treatment

✓ RT	38%
✓ CCRT	17%
✓ CMT	5%
✓ I-131	4%
✓ Other	32%
✓ Combine treatment	4%

Note: Other = Consult/ Intervention/Surgery/Palliative Care

New cancer patients in Lampang Cancer Hospital, 2022


All new cancer patients undergoing service in Lampang Cancer Hospital in 2022 have 2,713 cases (21.9% of all new cases) and equal 3.5% of all outpatients. In addition, the number of new cancer patients in 2022 increased from 2012 by 56.26%



Cases	Number	Percentage (%)
Number of all outpatients	77,884	100.0
Number of all new cases (Checkup, cancer cases and other disease)	12,404	15.9
Number of new cancer cases	2,713	3.5 (of all outpatients) 21.9 (of all new cases)


New cancer patients in Lampang Cancer Hospital by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
0 - 4	2	0.07	0	0.00	2	0.07
5 - 9	0	0.00	0	0.00	0	0.00
10 - 14	1	0.04	2	0.07	3	0.11
15 - 19	3	0.11	3	0.11	6	0.22
20 - 24	2	0.07	15	0.55	17	0.62
25 - 29	5	0.18	19	0.70	24	0.88
30 - 34	11	0.41	50	1.84	61	2.25
35 - 39	22	0.81	81	2.99	103	3.80
40 - 44	42	1.55	135	4.98	177	6.53
45 - 49	55	2.03	173	6.38	228	8.41
50 - 54	97	3.57	220	8.11	317	11.68
55 - 59	155	5.71	262	9.66	417	15.37
60 - 64	205	7.56	268	9.88	473	17.44
65 - 69	206	7.59	204	7.52	410	15.11
70 - 74	141	5.20	103	3.80	244	9.00
75 - 79	77	2.84	64	2.36	141	5.20
80 - 84	38	1.40	24	0.88	62	2.28
85 +	13	0.48	15	0.55	28	1.03
Total	1,075	39.62	1,638	60.38	2,713	100



Location of new cancer patients in Lampang Cancer Hospital, 2022


Provinces	Male		Female		Total	
	N	%	N	%	N	%
Lampang	311	11.46	419	15.44	730	26.90
Chiang Rai	220	8.10	389	14.34	609	22.44
Phayao	146	5.38	179	6.60	325	11.98
Phrae	105	3.87	178	6.56	283	10.43
Nan	88	3.24	141	5.20	229	8.44
Chiang Mai	66	2.43	100	3.68	166	6.11
Lamphun	21	0.77	56	2.06	77	2.83
Mae Hong Son	4	0.15	10	0.36	14	0.51
Uttaradit	56	2.06	56	2.06	112	4.12
Tak	21	0.77	20	0.73	41	1.50
Sukhothai	16	0.59	17	0.62	33	1.21
Phitsanulok	2	0.07	5	0.18	7	0.25
Phetchabun	3	0.11	2	0.07	5	0.18
Kamphaeng Phet	3	0.11	37	1.36	40	1.47
Bangkok	3	0.11	7	0.26	10	0.37
Nakhon Sawan	0	0.00	3	0.11	3	0.11
Khon Kaen	1	0.04	1	0.04	2	0.08
Maha Sarakham	1	0.04	1	0.04	2	0.08
Nakhon Pathom	1	0.04	1	0.04	2	0.08
Phichit	0	0.00	2	0.08	2	0.08
Prachin Buri	0	0.00	2	0.08	2	0.08
Suphan Buri	1	0.04	1	0.04	2	0.08
Udon Thani	0	0.00	2	0.08	2	0.08
Chachoengsao	0	0.00	1	0.04	1	0.04
Chon Buri	0	0.00	1	0.04	1	0.04
Lop Buri	1	0.04	0	0.00	1	0.04
Narathiwat	1	0.04	0	0.00	1	0.04
Nonthaburi	1	0.04	0	0.00	1	0.04
Pathum Thani	0	0.00	1	0.04	1	0.04
Phuket	1	0.04	0	0.00	1	0.04
Roi Et	1	0.04	0	0.00	1	0.04
Surat Thani	0	0.00	1	0.04	1	0.04
Trang	1	0.04	0	0.00	1	0.04
Uthai Thani	0	0.00	1	0.04	1	0.04
Lao	0	0.00	4	0.15	4	0.15
Total	1,075	39.62	1,638	60.38	2,713	100



Note: Other provinces were, Phetchabun, Bangkok, Nakhon Sawan, Khon Kaen, Maha Sarakham, Nakhon Pathom, Phichit, Prachin Buri, Suphan Buri, Udon Thani, Chachoengsao, Chon Buri, Lop Buri, Narathiwat, Nonthaburi, Pathum Thani, Phuket, Roi Et, Surat Thani, Trang, Uthai Thani, and Lao


Number and Percentage of Histological verified since 2013 - 2022

Year	Number of new cancer cases	Number of histological verified	Percentage
2013	1,908	1,615	84.64
2014	2,201	1,856	84.33
2015	2,583	2,331	90.24
2016	2,487	2,180	87.66
2017	2,290	2,018	88.12
2018	2,207	1,973	89.4
2019	2,426	2,169	89.41
2020	2,690	2,415	89.78
2021	2,646	2,475	93.54
2022	2,713	2,542	93.73




Type of Diagnosis, 2022

Type of Diagnosis	Male	Female	Total	Percentage
Histology of primary	921	1,504	2,425	89.39
Clinical investigation	97	65	162	5.97
Histology of metastasis	39	43	82	3.02
Cytology and hematology	16	20	36	1.33
Surgery without histology	2	6	8	0.29
Total	1,075	1,638	2,713	100
Histological proof	976	1,567	2,543	93.73
No histological proof	99	71	170	6.27




Staging of new cancer patients in Lampang Cancer Hospital, 2022




Extension of new cancer patients in Lampang Cancer Hospital, 2022

Extension	Male	Female	Total	%
Localized	95	341	436	16.07
Direct extension	63	129	192	7.08
Regional lymph node	265	582	847	31.22
Distant metastasis	487	418	905	33.36
Not applicable	24	20	44	1.62
Not known	141	148	289	10.65
Total	1,075	1,638	2,713	100



Metastasis sites in stage IV, 2022


Metastasis site	Male	Female	Total	%
Distant lymph node	51	68	119	13.15
Bone	154	98	252	27.85
Liver	20	17	37	4.09
Lung/Pleura	41	27	68	7.51
Brain	48	37	85	9.39
Peritoneum	3	6	9	0.99
Other	6	8	14	1.55
Multiple sites	164	157	321	35.47
Total	487	418	905	100



Type of treatment in Lampang Cancer Hospital, 2022


Treatment	Male	Female	Total	%
RT	371	666	1037	38.22
CCRT	203	248	451	16.62
CMT	68	69	137	5.05
I-131	19	85	104	3.83
Palliative Care	10	9	19	0.7
Surgery	1	13	14	0.52
Hormone	1	2	3	0.11
Immunotherapy	3	0	3	0.11
RT + CMT	13	20	33	1.22
CMT + CCRT	18	6	24	0.88
Surgery + CMT	3	19	22	0.81
Targeted Therapy	8	5	13	0.48
Surgery + RT + CMT	0	7	7	0.26
RT + CMT + Hormone	0	5	5	0.18
RT + CMT + Targeted Therapy	0	3	3	0.11
RT + Hormone	1	2	3	0.11
Surgery + CCRT	2	1	3	0.11
CMT + Targeted Therapy	0	1	1	0.04
CMT + Targeted Therapy + Hormone	0	1	1	0.04
Hormone + Targeted Therapy	0	1	1	0.04
RT + CMT + Hormone + Targeted Therapy	0	1	1	0.04
Surgery + CCRT + CMT	1	0	1	0.04
Surgery + Hormone	0	1	1	0.04
Surgery + RT	1	0	1	0.04
Investigation	249	380	629	23.18
Consult	103	93	196	7.22
Total	1,075	1,638	2,713	100

Note: RT = Radiotherapy, CMT = Chemotherapy, CCRT = Concurrent Chemoradiotherapy,
Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan



Note: Other = Consult/ Intervention

10 Leading new cancer patients in Lampang Cancer Hospital by Sex, 2022





Male			
Rating	Cancer sites	Number	%
1	Colorectal	221	20.56
2	Prostate	185	17.21
3	Trachea, Bronchus and lung	183	17.02
4	Oral cavity and Pharynx	116	10.79
5	Liver and bile duct	88	8.19
6	Oesophagus	44	4.09
7	Lymphoma	43	4.00
8	Bladder	24	2.23
9	Thyroid	23	2.14
10	Stomach	19	1.77

Female			
Rating	Cancer sites	Number	%
1	Breast	761	46.46
2	Cervix uteri	211	12.88
3	Colorectal	127	7.75
4	Trachea, Bronchus and lung	127	7.75
5	Thyroid	97	5.92
6	Corpus uteri	66	4.03
7	Oral cavity and Pharynx	48	2.93
8	Liver and bile duct	30	1.83
9	Lymphoma	30	1.83
10	Stomach	20	1.22

Note: Lpch has Colorectal cancer screening policy and Nakhonping has referred Prostate cancer for investigation in LPCH this year.

10 Leading new cancer patients in Lampang Cancer Hospital (Both sex), 2022



Rating	Cancer sites	Number	Percentage
1	Breast	763	28.12
2	Colorectal	349	12.86
3	Trachea, Bronchus and lung	309	11.39
4	Cervix uteri	210	7.74
5	Prostate	185	6.82
6	Oral cavity and Pharynx	164	6.04
7	Thyroid	120	4.42
8	Liver and bile duct	118	4.35
9	Lymphoma	79	2.91
10	Corpus uteri	66	2.43


Common Cancer Sites in Lampang Cancer Hospital 2022



Hospital-Based Cancer Registry 2022
Lampang Cancer Hospital


Head and Neck Cancer ICD-O: C00-14, C30-32

Trend of new head and neck cancer in LPCH 20 years (since 2003 - 2022)




Number of new head and neck cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
20 - 24	0	0.00	2	1.02	2	1.02
25 - 29	1	0.51	1	0.51	2	1.02
30 - 34	1	0.51	2	1.02	3	1.53
35 - 39	5	2.57	0	0.00	5	2.57
40 - 44	13	6.67	2	1.02	15	7.69
45 - 49	15	7.69	3	1.54	18	9.23
50 - 54	20	10.26	8	4.11	28	14.37
55 - 59	24	12.31	8	4.11	32	16.42
60 - 64	18	9.23	8	4.11	26	13.34
65 - 69	19	9.74	7	3.59	26	13.33
70 - 74	15	7.69	3	1.54	18	9.23
75 - 79	6	3.08	3	1.54	9	4.62
80 - 84	3	1.54	4	2.05	7	3.59
85 +	2	1.02	2	1.02	4	2.04
Total	142	72.82	53	27.18	195	100



Type of diagnosis of new head and neck cancer patients in LPCH by age and sex, 2022


Type of Diagnosis	Male	Female	Total	%
Cytology and hematology	2	0	2	1.03
Histology of metastasis	1	3	4	2.05
Histology of primary	139	50	189	96.92
Total	142	53	195	100



Treatment of new head and neck cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
RT	35	17	52	26.67
CMT	4	2	6	3.08
CCRT	56	23	79	40.51
Palliative Care	1	0	1	0.51
Immunotherapy	1	0	1	0.51
Other	34	8	42	21.54
Combine Treatment	11	3	14	7.18
Total	142	53	195	100

Note: RT = Radiotherapy, CMT: Chemotherapy,
CCRT = Concurrent Chemoradiotherapy,
Other = Consult/Investigation




Staging of new head and neck cancer patients in LPCH by age and sex, 2022

Staging	Male	Female	Total	%
Stage I	6	1	7	3.59
Stage II	11	6	17	8.72
Stage III	32	10	42	21.54
Stage IV	88	35	123	63.07
Unknown Stage	5	1	6	3.08
Total	142	53	195	100




Extension of new head and neck cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	17	8	25	12.82
Direct extension	15	9	24	12.31
Regional lymph node	85	28	113	57.94
Distant metastasis	20	7	27	13.85
Not known	5	1	6	3.08
Total	142	53	195	100




Metastasis sites of new head and neck cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Distant lymph node	6	5	11	40.74
Bone	5	0	5	18.52
Lung/Pleura	3	0	3	11.11
Brain	1	0	1	3.70
Multiple sites	5	2	7	25.93
Total	20	7	27	100




Colorectal Cancer ICD-O: C18-20

Trend of new colorectal cancer in LPCH 20 years (since 2003 - 2022)




Number of new colorectal cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
10 - 14	0	0.00	1	0.29	1	0.29
15 - 19	2	0.58	0	0.00	2	0.58
20 - 24	0	0.00	2	0.58	2	0.58
25 - 29	1	0.29	0	0.00	1	0.29
30 - 34	2	0.58	1	0.29	3	0.87
35 - 39	3	0.86	4	1.15	7	2.01
40 - 44	5	1.44	4	1.15	9	2.59
45 - 49	12	3.46	9	2.59	21	6.05
50 - 54	26	7.49	17	4.90	43	12.39
55 - 59	27	7.78	22	6.34	49	14.12
60 - 64	47	13.54	21	6.05	68	19.59
65 - 69	40	11.53	20	5.76	60	17.29
70 - 74	28	8.07	14	4.03	42	12.10
75 - 79	19	5.48	7	2.02	26	7.50
80 - 84	7	2.02	3	0.86	10	2.88
85 +	1	0.29	2	0.58	3	0.87
Total	220	63.41	127	36.59	347	100



Type of diagnosis of new colorectal cancer patients in LPCH by age and sex, 2022


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	2	0	2	0.58
Histology of metastasis	3	3	6	1.73
Histology of primary	215	124	339	97.69
Total	220	127	347	100



Treatment of new colorectal cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
RT	73	44	117	33.72
CMT	17	5	22	6.34
CCRT	81	51	132	38.04
Palliative Care	0	3	3	0.86
Other	41	19	60	17.29
Combine Treatment	8	5	13	3.75
Total	220	127	347	100

Note: RT = Radiotherapy, CMT: Chemotherapy,
CCRT = Concurrent Chemoradiotherapy,
Other = Consult/Investigation




Staging of new colorectal cancer patients in LPCH by age and sex, 2022

Staging	Male	Female	Total	%
Stage I	4	4	8	2.31
Stage II	25	19	44	12.68
Stage III	103	50	153	44.09
Stage IV	63	38	101	29.11
Unknown Stage	25	16	41	11.81
Total	220	127	347	100




Extension of new colorectal cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	17	13	30	8.65
Direct extension	16	10	26	7.49
Regional lymph node	99	48	147	42.36
Distant metastasis	62	39	101	29.11
Not known	26	17	43	12.39
Total	220	127	347	100




Metastasis sites of new colorectal cancer patients in LPCH by age and sex, 2022

Metastasis site	Male	Female	Total	%
Distant lymph node	7	5	12	11.88
Bone	3	3	6	5.94
Liver	7	8	15	14.85
Lung/Pleura	10	2	12	11.88
Brain	2	0	2	1.98
Peritoneum	0	3	3	2.97
Other	1	1	2	1.98
Multiple sites	32	17	49	48.52
Total	62	39	101	100




Liver and bile ducts Cancer ICD-O: C22, C24

Trend of new liver and bile ducts cancer in LPCH 20 years (since 2002 - 2022)




Number of new liver and bile ducts cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
0 - 4	1	0.8	0	0.0	1	0.8
5 - 9	1	0.8	0	0.0	1	0.8
10 - 14	1	0.8	0	0.0	1	0.8
15 - 19	1	0.8	0	0.0	1	0.8
20 - 24	1	0.8	0	0.0	1	0.8
25 - 29	1	0.8	0	0.0	1	0.8
30 - 34	1	0.8	0	0.0	1	0.8
35 - 39	2	1.7	0	0.0	2	1.7
40 - 44	4	3.4	0	0.0	4	3.4
45 - 49	8	6.8	2	1.7	10	8.5
50 - 54	7	5.9	5	4.3	12	10.2
55 - 59	13	11.0	7	5.9	20	16.9
60 - 64	19	16.2	7	5.9	26	22.1
65 - 69	21	17.8	5	4.3	26	22.1
70 - 74	8	6.8	2	1.7	10	8.5
75 - 79	1	0.8	2	1.7	3	2.5
80 - 84	3	2.5	0	0.0	3	2.5
Total	88	74.50	30	25.50	118	100




Type of diagnosis of new liver and bile ducts cancer patients in LPCH by age and sex, 2022

Type of Diagnosis	Male	Female	Total	%
Clinical investigation	49	18	67	56.78
Histology of metastasis	6	5	11	9.32
Histology of primary	33	7	40	33.90
Total	88	30	118	100



Treatment of new liver and bile ducts cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
RT	25	6	31	26.27
CMT	19	6	25	21.19
CCRT	0	1	1	0.85
Palliative Care	5	1	6	5.08
Targeted Therapy	1	0	1	0.85
Other	36	15	51	43.22
Combine Treatment	2	1	3	2.55
Total	88	30	118	100



Note: RT = Radiotherapy, CMT: Chemotherapy,
CCRT = Concurrent Chemoradiotherapy,
Other = Consult/Investigation


Staging of new liver and bile ducts cancer patients in LPCH by age and sex, 2022

Staging	Male	Female	Total	%
Stage I	1	0	1	0.85
Stage II	1	1	2	1.69
Stage III	7	0	7	5.93
Stage IV	63	26	89	75.43
Unknown Stage	16	3	19	16.10
Total	88	30	118	100




Extension of new liver and bile ducts cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	6	1	7	5.93
Direct extension	2	1	3	2.54
Regional lymph node	6	0	6	5.08
Distant metastasis	57	25	82	69.50
Not known	17	3	20	16.95
Total	88	30	118	100




Metastasis sites of new liver and bile ducts cancer patients in LPCH by age and sex, 2022

Metastasis site	Male	Female	Total	%
Distant lymph node	5	2	7	8.54
Bone	11	6	17	20.73
Liver	4	2	6	7.32
Lung/Pleura	5	2	7	8.54
Peritoneum	3	0	3	3.65
Other	3	1	4	4.88
Multiple sites	26	12	38	46.34
Total	57	25	82	100




Lung Cancer ICD-O: C33 - 34

Trend of new lung cancer in LPCH 20 years (since 2002 - 2022)




Number of new lung cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
30 - 34	2	0.65	1	0.32	3	0.97
35 - 39	3	0.97	1	0.32	4	1.29
40 - 44	4	1.29	4	1.29	8	2.58
45 - 49	5	1.61	10	3.23	15	4.84
50 - 54	16	5.16	8	2.58	24	7.74
55 - 59	29	9.35	21	6.77	50	16.12
60 - 64	45	14.52	23	7.42	68	21.94
65 - 69	43	13.87	23	7.42	66	21.29
70 - 74	22	7.10	20	6.45	42	13.55
75 - 79	11	3.55	8	2.58	19	6.13
80 - 84	1	0.32	5	1.61	6	1.93
85 +	2	0.65	3	0.97	5	1.62
Total	183	59.04	127	40.96	310	100



Type of diagnosis of new lung cancer patients in LPCH by age and sex, 2022


Type of Diagnosis	Male	Female	Total	%
Clinical investigation	34	27	61	19.68
Cytology and hematology	10	7	17	5.48
Histology of metastasis	20	16	36	11.61
Histology of primary	119	77	196	63.23
Total	183	127	310	100



Treatment of new lung cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
RT	100	66	166	53.55
CMT	17	17	34	10.97
CCRT	12	4	16	5.16
Palliative Care	2	1	3	0.97
Targeted Therapy	7	2	9	2.90
Other	35	31	66	21.29
Combine Treatment	10	6	16	5.17
Total	183	127	310	100

Note: RT = Radiotherapy, CMT: Chemotherapy,
CCRT = Concurrent Chemoradiotherapy,
Other = Consult/Investigation




Staging of new lung cancer patients in LPCH by age and sex, 2022

Staging	Male	Female	Total	%
Stage I	0	1	1	0.32
Stage II	3	5	8	2.58
Stage III	30	17	47	15.16
Stage IV	141	97	238	76.78
Unknown Stage	9	7	16	5.16
Total	183	127	310	100




Extension of new lung cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	1	2	3	0.97
Direct extension	3	4	7	2.26
Regional lymph node	27	16	43	13.87
Distant metastasis	142	96	238	76.77
Not known	10	9	19	6.13
Total	183	127	310	100




Metastasis sites of new lung cancer patients in LPCH by age and sex, 2022

Metastasis site	Male	Female	Total	%
Distant lymph node	12	8	20	8.40
Bone	20	7	27	11.34
Liver	2	0	2	0.84
Lung/Pleura	16	9	25	10.50
Brain	40	26	66	27.74
Other	1	2	3	1.26
Multiple sites	51	44	95	39.92
Total	142	96	238	100




Breast Cancer ICD-O: C50

Trend of new breast cancer in LPCH 20 years (since 2002 - 2022)




Number of new breast cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
20 - 24	0	0.00	3	0.39	3	0.39
25 - 29	0	0.00	6	0.79	6	0.79
30 - 34	0	0.00	22	2.89	22	2.89
35 - 39	0	0.00	42	5.51	42	5.51
40 - 44	0	0.00	93	12.20	93	12.20
45 - 49	0	0.00	104	13.65	104	13.65
50 - 54	0	0.00	121	15.88	121	15.88
55 - 59	0	0.00	133	17.46	133	17.46
60 - 64	0	0.00	99	12.99	99	12.99
65 - 69	0	0.00	82	10.76	82	10.76
70 - 74	1	0.13	32	4.20	33	4.33
75 - 79	0	0.00	16	2.10	16	2.10
80 - 84	0	0.00	7	0.92	7	0.92
85 +	0	0.00	1	0.13	1	0.13
Total	1	0.13	761	99.87	762	100




Type of diagnosis of new breast cancer patients in LPCH by age and sex, 2022

Type of Diagnosis	Male	Female	Total	%
Clinical only	0	1	1	0.13
Clinical investigation	0	3	3	0.39
Surgery without histology	0	4	4	0.52
Cytology and hematology	0	4	4	0.52
Histology of metastasis	0	2	2	0.26
Histology of primary	1	747	748	98.16
Total	1	761	762	100



Treatment of new breast cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
Surgery	0	11	11	1.44
RT	1	368	369	48.43
CMT	0	17	17	2.23
Hormone	0	2	2	0.26
Palliative Care	0	2	2	0.26
Targeted Therapy	0	1	1	0.13
Other	0	316	316	41.47
Combine Treatment	0	43	43	5.65
Total	1	761	762	100



Note: RT = Radiotherapy, CMT: Chemotherapy,
Other = Consult/Investigation


Extension of new breast cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	0	193	193	25.33
Direct extension	0	32	32	4.20
Regional lymph node	1	364	365	47.90
Distant metastasis	0	134	134	17.58
Not known	0	38	38	4.99
Total	1	761	762	100




Metastasis sites of new breast cancer patients in LPCH by age and sex, 2022

Metastasis site	Male	Female	Total	%
Distant lymph node	0	15	15	11.19
Bone	0	70	70	52.24
Liver	0	3	3	2.24
Lung/Pleura	0	6	6	4.48
Brain	0	3	3	2.24
Other	0	2	2	1.49
Multiple sites	0	35	35	26.12
Total	0	134	134	100




Staging of diagnosis of new breast cancer patients in LPCH, 2022

Type of treatment	Male	Female	Total	%
Stage I	0	5	5	0.66
Stage IA	0	80	80	10.50
Stage IC	0	1	1	0.13
Stage II	0	6	6	0.79
Stage IIA	0	151	151	19.82
Stage IIB	0	138	138	18.11
Stage III	0	7	7	0.92
Stage IIIA	1	121	122	16.01
Stage IIIB	0	39	39	5.12
Stage IIIC	0	51	51	6.69
Stage IV	0	82	82	10.76
Stage IVB	0	52	52	6.82
Not known stage	0	28	28	3.67
Total	1	761	762	100




Comparison number of new breast cancer patients in LPCH by staging since 2013 - 2022




Cervical Cancer ICD-O: C53

Trend of new cervical cancer in LPCH 20 years (since 2002 - 2022)




Number of new cervical cancer patients in LPCH by age and sex, 2022

Age group (Year)	N	%
25 - 29	6	2.84
30 - 34	12	5.69
35 - 39	21	9.95
40 - 44	15	7.11
45 - 49	23	10.90
50 - 54	20	9.48
55 - 59	32	15.17
60 - 64	37	17.54
65 - 69	23	10.90
70 - 74	11	5.21
75 - 79	6	2.84
80 - 84	2	0.95
85 +	3	1.42
Total	211	100



Type of diagnosis of new cervical cancer patients in LPCH by age and sex, 2022


Type of Diagnosis	Total	%
Clinical investigation	4	1.90
Surgery without histology	1	0.47
Histology of primary	206	97.63
Total	211	100



Treatment of new cervical cancer patients in LPCH by age and sex, 2022


Type of treatment	Total	%
RT	39	18.48
CMT	4	1.90
CCRT	147	69.67
Other	18	8.53
Combine Treatment	3	1.42
Total	211	100

Note: RT = Radiotherapy, CMT: Chemotherapy, CCRT = Concurrent Chemoradiotherapy, Other = Consult/Investigation




Extension of new cervical cancer patients in LPCH by age and sex, 2022

Extension	Total	%
Localized	40	18.96
Direct extension	52	24.64
Regional lymph node	68	32.23
Distant metastasis	23	10.90
Not known	28	13.27
Total	211	100




Metastasis sites of new cervical cancer patients in LPCH by age and sex, 2022

Metastasis site	Total	%
Distant lymph node	4	17.39
Bone	4	17.39
Lung/Pleura	2	8.70
Other	1	4.35
Multiple sites	12	52.17
Total	23	100




Staging of diagnosis of new cervical cancer patients in LPCH, 2022

Type of treatment	Total	%
Stage IA	2	0.95
Stage IB	27	12.80
Stage II	2	0.95
Stage IIA	18	8.53
Stage IIB	48	22.74
Stage IIC	2	0.95
Stage III	1	0.47
Stage IIIA	4	1.90
Stage IIIB	27	12.80
Stage IIIC	40	18.95
Stage IV	4	1.90
Stage IVA	16	7.58
Stage IVB	17	8.06
Not known stage	3	1.42
Total	211	100




Comparison number of new cervical cancer patients in LPCH by staging since 2013 - 2022




Thyroid Cancer ICD-O: C73

Trend of new thyroid cancer in LPCH 20 years (since 2002 - 2022)




Number of new thyroid cancer patients in LPCH by age and sex, 2022

Age group (Year)	Male		Female		Both sex	
	N	%	N	%	N	%
10 - 14	0	0.00	1	0.83	1	0.8
15 - 19	0	0.00	3	2.50	3	2.5
20 - 24	0	0.00	4	3.33	4	3.3
25 - 29	1	0.83	5	4.17	6	5.0
30 - 34	2	1.67	8	6.67	10	8.3
35 - 39	2	1.67	10	8.34	12	10.0
40 - 44	3	2.50	6	5.00	9	7.5
45 - 49	3	2.50	7	5.83	10	8.3
50 - 54	2	1.67	15	12.50	17	14.2
55 - 59	3	2.50	7	5.83	10	8.3
60 - 64	2	1.67	15	12.50	17	14.2
65 - 69	1	0.83	7	5.83	8	6.7
70 - 74	3	2.50	4	3.33	7	5.8
75 - 79	0	0.00	5	4.17	5	4.2
80 - 84	1	0.83	0	0.00	1	0.8
Total	23	19.17	97	80.83	120	100



Type of diagnosis of new thyroid cancer patients in LPCH by age and sex, 2022


Type of Diagnosis	Male	Female	Total	%
Cytology and hematology	1	7	8	6.67
Histology of metastasis	0	3	3	2.50
Histology of primary	22	87	109	90.83
Total	23	97	120	100



Treatment of new thyroid cancer patients in LPCH by age and sex, 2022


Type of treatment	Male	Female	Total	%
Surgery	0	1	1	0.83
RT	2	3	5	4.17
I-131	19	85	104	86.67
Palliative Care	0	1	1	0.83
Other	2	7	9	7.50
Total	23	97	120	100

Note: RT = Radiotherapy,
Other = Consult/Investigation




Staging of new thyroid cancer patients in LPCH by age and sex, 2022

Staging	Male	Female	Total	%
Stage I	6	42	48	40.00
Stage II	1	13	14	11.67
Stage III	1	5	6	5.00
Stage IV	12	32	44	36.67
Unknown Stage	3	5	8	6.66
Total	23	97	120	100




Extension of new thyroid cancer patients in LPCH by age and sex, 2022

Extension	Male	Female	Total	%
Localized	3	37	40	33.33
Direct extension	0	5	5	4.17
Regional lymph node	4	17	21	17.50
Distant metastasis	12	33	45	37.50
Not known	4	5	9	7.50
Total	23	97	120	100



Metastasis sites of new thyroid cancer patients in LPCH by age and sex, 2022

Metastasis site	Male	Female	Total	%
Distant lymph node	6	19	25	55.56
Bone	0	2	2	4.44
Lung/Pleura	2	4	6	13.33
Multiple sites	4	8	12	26.67
Total	12	33	45	100



Number of new cancer by age and sex in Lampang Cancer Hospital (Male), 2022

SITE	ALL AGE	AGE UNK	0- -4	5- -9	10- -14	15- -19	20- -24	25- -29	30- -34	35- -39	40- -44	45- -49	50- -54	55- -59	60- -64	65- -69	70- -74	75- -79	80- -84	85+	% of Total	ICD (10th)
Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.2	C00
Tongue	17	0	0	0	0	0	0	0	0	0	1	3	3	4	1	2	2	1	0	0	1.6	C01-02
Mouth	11	0	0	0	0	0	0	0	0	0	1	2	1	4	1	1	0	1	0	0	1.0	C03-06
Salivary glands	7	0	0	0	0	0	0	0	0	1	1	0	0	1	0	1	2	0	1	0	0.7	C07-08
Tonsil	12	0	0	0	0	0	0	0	0	0	1	3	1	2	3	1	1	0	0	0	1.1	C09
Other oropharynx	7	0	0	0	0	0	0	0	0	1	0	1	1	2	1	1	0	0	0	0	0.7	C10
Nasopharynx	50	0	0	0	0	0	0	1	1	3	5	3	9	5	7	5	6	3	2	0	4.6	C11
Hypopharynx	10	0	0	0	0	0	0	0	0	0	1	0	1	3	1	1	1	1	0	1	0.9	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C14
Oesophagus	44	0	0	0	0	0	0	0	0	0	4	1	9	7	8	10	5	0	0	0	4.1	C15
Stomach	19	0	0	0	0	0	0	0	0	0	0	0	2	6	3	6	2	0	0	0	1.8	C16
Small intestine	2	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0.2	C17
Colon	41	0	0	0	0	1	0	0	0	0	1	2	10	4	9	5	5	4	0	0	3.8	C18
Rectum	180	0	0	0	0	1	0	1	2	3	4	10	16	24	38	35	23	15	7	1	16.7	C19-20
Anus	9	0	0	0	0	0	0	0	0	2	0	2	0	0	1	2	1	0	1	0	0.8	C21
Liver and bile duct	88	0	1	0	0	0	0	0	1	2	4	8	7	13	19	21	8	1	3	0	8.2	C22, C24
Gallbladder	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0.3	C23
Pancreas	10	0	0	0	0	0	0	0	0	0	0	0	1	3	2	3	0	1	0	0	0.9	C25
Nose, sinuses etc.	7	0	0	0	0	0	0	0	0	0	1	0	1	1	1	3	0	0	0	0	0.7	C30-31
Larynx	19	0	0	0	0	0	0	0	0	0	2	3	3	2	3	3	3	0	0	0	1.8	C32
Trachea, Bronchus and lung	183	0	0	0	0	0	0	0	2	3	4	5	16	29	45	43	22	11	1	2	17.0	C33-34
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C37-38
Bone	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.2	C40-C41
Melanoma of skin	9	0	0	0	0	0	0	0	0	0	0	0	0	3	2	2	1	0	1	0	0.8	C43
Other skin	17	0	0	0	0	1	0	0	0	1	2	1	0	1	1	4	1	1	1	3	1.6	C44
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C45
Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C46
Connective tissue	11	0	0	0	0	0	0	0	0	0	1	0	1	4	3	1	1	0	0	0	1.0	C47, C49
Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C50
Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C51
Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C52
Cervix uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C53
Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C56
Penis	7	0	0	0	0	0	0	0	0	0	0	1	1	2	0	2	0	0	1	0	0.7	C60
Prostate	185	0	0	0	0	0	0	0	0	0	0	1	2	20	35	40	40	30	14	3	17.2	C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C62
Kidney	6	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	1	0	0	0	0.6	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C66
Bladder	24	0	0	0	0	0	0	0	0	0	0	2	3	5	1	5	2	5	1	0	2.2	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C68
Eye and adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C69
Brain, nervous system	12	0	1	0	0	0	0	0	1	2	1	1	1	1	2	1	1	0	0	0	1.1	C70-72
Thyroid	23	0	0	0	0	0	0	1	2	2	3	3	2	3	2	1	3	0	1	0	2.1	C73
Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C75
Hodgkin disease	3	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0.3	C81
Non-Hodgkin lymphoma	40	0	0	0	0	0	2	0	2	2	3	3	6	3	7	3	7	2	0	0	3.7	C82-85, C96
Multiple myeloma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0.2	C90
Lymphoid leukemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C91
Myeloid leukemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C92-94
Other and unspecified	10	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	1	1	2	1	0.9	O&U
All sites	1,075	0	2	0	1	3	2	5	11	22	42	55	97	155	205	206	141	77	38	13	100	ALL

Number of new cancer by age and sex in Lampang Cancer Hospital (Female), 2022

SITE	ALL AGE	AGE UNK	0- 4	5- 9	10- 14	15- 19	20- 24	25- 29	30- 34	35- 39	40- 44	45- 49	50- 54	55- 59	60- 64	65- 69	70- 74	75- 79	80- 84	85+	% of Total	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.1	C00
Tongue	5	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	0	0	0.3	C01-02
Mouth	9	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0	0	1	2	0.5	C03-06
Salivary glands	10	0	0	0	0	0	1	0	1	0	0	1	1	0	0	2	1	2	1	0	0.6	C07-08
Tonsil	3	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0.2	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.1	C10
Nasopharynx	16	0	0	0	0	0	1	0	1	0	1	0	5	1	5	1	1	0	0	0	1.0	C11
Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0.1	C12-13
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C14
Oesophagus	8	0	0	0	0	0	0	0	0	0	0	0	2	0	3	1	0	1	1	0	0.5	C15
Stomach	20	0	0	0	0	0	0	0	0	0	1	1	3	3	4	2	4	2	0	0	1.2	C16
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C17
Colon	25	0	0	0	0	0	0	0	0	0	1	1	2	3	8	4	2	2	0	2	1.5	C18
Rectum	102	0	0	0	1	0	2	0	1	4	3	8	15	19	13	16	12	5	3	0	6.2	C19-20
Anus	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0	0	0.2	C21
Liver and bile duct	30	0	0	0	0	0	0	0	0	0	0	2	5	7	7	5	2	2	0	0	1.8	C22, C24
Gallbladder	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0.2	C23
Pancreas	4	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0.2	C25
Nose, sinuses etc.	5	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1	1	0	0.3	C30-31
Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C32
Trachea, Bronchus and lung	127	0	0	0	0	0	0	0	1	1	4	10	8	21	23	23	20	8	5	3	7.8	C33-34
Other thoracic organs	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0.2	C37-38
Bone	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C40-C41
Melanoma of skin	6	0	0	0	0	0	0	0	0	0	1	0	0	1	0	3	1	0	0	0	0.4	C43
Other skin	10	0	0	0	0	0	1	0	0	0	0	1	0	1	0	2	2	1	0	2	0.6	C44
Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C45
Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C46
Connective tissue	14	0	0	0	0	0	2	0	1	1	0	1	2	3	2	1	1	0	0	0	0.9	C47, C49
Breast	761	0	0	0	0	0	3	6	22	42	93	104	121	133	99	82	32	16	7	1	46.5	C50
Vulva	8	0	0	0	0	0	0	0	0	0	0	2	1	0	3	0	0	1	1	0	0.5	C51
Vagina	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0.1	C52
Cervix uteri	211	0	0	0	0	0	0	6	12	21	15	23	20	32	37	23	11	6	2	3	12.9	C53
Corpus uteri	66	0	0	0	0	0	1	0	0	0	1	0	6	17	22	14	1	4	0	0	4.0	C54
Uterus unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C55
Ovary	12	0	0	0	0	0	0	0	1	0	1	2	1	1	4	2	0	0	0	0	0.7	C56
Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C62
Kidney	4	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	0	0.2	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C65
Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C66
Bladder	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0.2	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C68
Eye and adnexa	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1	C69
Brain, nervous system	9	0	0	0	0	0	0	0	1	0	3	0	2	0	2	1	0	0	0	0	0.5	C70-72
Thyroid	97	0	0	0	1	3	4	5	8	10	6	7	15	7	15	7	4	5	0	0	5.9	C73
Adrenal gland	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C75
Hodgkin disease	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C81
Non-Hodgkin lymphoma	28	0	0	0	0	0	0	0	1	2	1	4	4	0	5	4	2	4	0	1	1.7	C82-85, C96
Multiple myeloma	4	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0.2	C90
Lymphoid leukemia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	C91
Myeloid leukemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C92-94
Other and unspecified	15	0	0	0	0	0	0	0	0	0	0	3	1	2	3	2	0	3	0	1	0.9	O&U
All sites	1,638	0	0	0	2	3	15	19	50	81	135	173	220	262	268	204	103	64	24	15	100	ALL

Pathology according to site and sex, 2022

PATHOLOGY AND SITES	Male	Female	Total
Total	1,075	1,638	2,713
C00 LIP	2	1	3
8070: Squamous cell carcinoma, NOS	1	1	2
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1
C01 BASE OF TONGUE	3	0	3
8070: Squamous cell carcinoma, NOS	3	0	3
C02 OTHER AND UNSPECIFIED PARTS OF TONGUE	14	5	19
8070: Squamous cell carcinoma, NOS	14	5	19
C03 GUM	0	3	3
8070: Squamous cell carcinoma, NOS	0	3	3
C04 FLOOR OF MOUTH	3	0	3
8070: Squamous cell carcinoma, NOS	3	0	3
C05 PALATE	5	2	7
8070: Squamous cell carcinoma, NOS	5	1	6
8200: Adenoid cystic carcinoma	0	1	1
C06 OTHER AND UNSPECIFIED PARTS OF MOUTH	3	4	7
8070: Squamous cell carcinoma, NOS	3	4	7
C07 PAROTID GLAND	3	8	11
8010: Carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	1	1	2
8082: Lymphoepithelial carcinoma	0	2	2
8200: Adenoid cystic carcinoma	0	2	2
8430: Mucoepidermoid carcinoma	0	3	3
8500: Salivary duct carcinoma	1	0	1
C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS	4	2	6
8070: Squamous cell carcinoma, NOS	1	0	1
8200: Adenoid cystic carcinoma	2	2	4
8430: Mucoepidermoid carcinoma	1	0	1
C09 TONSIL	12	3	15
8070: Squamous cell carcinoma, NOS	11	3	14
8430: Mucoepidermoid carcinoma	1	0	1
C10 OROPHARYNX	7	2	9
8070: Squamous cell carcinoma, NOS	7	2	9
C11 NASOPHARYNX	50	16	66
8010: Carcinoma, NOS	0	1	1
8020: Carcinoma, undifferentiated type, NOS	7	1	8
8070: Squamous cell carcinoma, NOS	4	5	9
8071: Squamous cell carcinoma, keratinizing, NOS	0	1	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	39	8	47
C12 PYRIFORM SINUS	6	1	7
8070: Squamous cell carcinoma, NOS	5	1	6
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1

PATHOLOGY AND SITES	Male	Female	Total
C13 HYPOPHARYNX	4	1	5
8070: Squamous cell carcinoma, NOS	4	1	5
C15 ESOPHAGUS	44	8	52
8070: Squamous cell carcinoma, NOS	43	7	50
8140: Adenocarcinoma, NOS	1	1	2
C16 STOMACH	19	20	39
8140: Adenocarcinoma, NOS	10	12	22
8144: Adenocarcinoma, intestinal type	2	0	2
8480: Mucinous adenocarcinoma	1	1	2
8490: Signet ring cell carcinoma	6	7	13
C17 SMALL INTESTINE	2	1	3
8936: Gastrointestinal stromal sarcoma	2	1	3
C18 COLON	41	25	66
8010: Carcinoma, NOS	0	1	1
8140: Adenocarcinoma, NOS	35	18	53
8240: Carcinoid tumor, NOS	0	1	1
8480: Mucinous adenocarcinoma	1	3	4
8481: Mucin-producing adenocarcinoma	4	2	6
8490: Signet ring cell carcinoma	1	0	1
C19 RECTOSIGMOID JUNCTION	13	3	16
8140: Adenocarcinoma, NOS	13	3	16
C20 RECTUM	166	99	265
8000: No histological proof	2	0	2
8010: Carcinoma, NOS	2	0	2
8140: Adenocarcinoma, NOS	157	95	252
8246: Neuroendocrine carcinoma	0	1	1
8480: Mucinous adenocarcinoma	0	1	1
8481: Mucin-producing adenocarcinoma	2	1	3
8490: Signet ring cell carcinoma	3	1	4
C21 ANUS AND ANAL CANAL	10	4	14
8070: Squamous cell carcinoma, NOS	6	3	9
8083: Basaloid squamous cell carcinoma	1	0	1
8140: Adenocarcinoma, NOS	2	0	2
8480: Mucinous adenocarcinoma	1	1	2
C22 LIVER AND INTRAHEPATIC BILE DUCTS	86	29	115
8000: No histological proof	49	17	66
8004: Malignant tumor, spindle cell type	1	0	1
8010: Carcinoma, NOS	0	1	1
8033: Sarcomatoid carcinoma	1	0	1
8140: Adenocarcinoma, NOS	15	6	21
8160: Cholangiocarcinoma	10	5	15
8170: Hepatocellular carcinoma, NOS	8	0	8
8560: Adenosquamous carcinoma	1	0	1
8970: Hepatoblastoma, NOS	1	0	1

PATHOLOGY AND SITES	Male	Female	Total
C23 GALLBLADDER	3	3	6
8000: No histological proof	0	2	2
8010: Carcinoma, NOS	1	0	1
8140: Adenocarcinoma, NOS	2	1	3
C24 OTHER AND UNSPECIFIED PARTS OF BILIARY TRACT	2	1	3
8000: No histological proof	0	1	1
8140: Adenocarcinoma, NOS	1	0	1
8160: Cholangiocarcinoma	1	0	1
C25 PANCREAS	10	4	14
8000: No histological proof	5	1	6
8010: Carcinoma, NOS	1	0	1
8140: Adenocarcinoma, NOS	3	2	5
8246: Neuroendocrine carcinoma	1	0	1
8452: Solid pseudopapillary carcinoma	0	1	1
C30 NASAL CAVITY AND MIDDLE EAR	3	2	5
8020: Carcinoma, undifferentiated type, NOS	0	1	1
8070: Squamous cell carcinoma, NOS	1	0	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
8720: Malignant melanoma, NOS	2	0	2
C31 ACCESSORY SINUSES	4	3	7
8020: Carcinoma, undifferentiated type, NOS	0	1	1
8070: Squamous cell carcinoma, NOS	2	1	3
8071: Squamous cell carcinoma, keratinizing, NOS	1	0	1
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	1	2
C32 LARYNX	19	0	19
8070: Squamous cell carcinoma, NOS	16	0	16
8071: Squamous cell carcinoma, keratinizing, NOS	2	0	2
8074: Squamous cell carcinoma, spindle cell	1	0	1
C34 BRONCHUS AND LUNG	182	127	309
8000: No histological proof	34	27	61
8010: Carcinoma, NOS	14	7	21
8012: Large cell carcinoma, NOS	0	1	1
8013: Large cell neuroendocrine carcinoma	0	1	1
8041: Small cell carcinoma, NOS	7	9	16
8046: Non-small cell carcinoma	23	14	37
8070: Squamous cell carcinoma, NOS	16	8	24
8071: Squamous cell carcinoma, keratinizing, NOS	0	1	1
8140: Adenocarcinoma, NOS	80	51	131
8200: Adenoid cystic carcinoma	0	1	1
8230: Solid carcinoma, NOS	0	1	1
8246: Neuroendocrine carcinoma	0	1	1
8480: Mucinous adenocarcinoma	1	2	3
8481: Mucin-producing adenocarcinoma	0	1	1
8490: Signet ring cell carcinoma	0	1	1
8550: Acinar cell carcinoma	1	0	1
8551: Acinar cell cystadenocarcinoma	2	1	3
8560: Adenosquamous carcinoma	3	0	3
8980: Carcinosarcoma, NOS	1	0	1

PATHOLOGY AND SITES	Male	Female	Total
C37 THYMUS	1	3	4
8070: Squamous cell carcinoma, NOS	1	0	1
8582: Thymoma, type AB, malignant	0	1	1
8583: Thymoma, type B1, malignant	0	1	1
8585: Thymoma, type B3, malignant	0	1	1
C38 HEART, MEDIASTINUM, AND PLEURA	1	0	1
8140: Adenocarcinoma, NOS	1	0	1
C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS	1	1	2
9180: Osteosarcoma, NOS	1	1	2
C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS	3	5	8
9732: Multiple myeloma	2	4	6
9823: Chronic lymphocytic leukemia	1	0	1
9861: Acute myeloid leukemia	0	1	1
C44 SKIN	26	16	42
8051: Verrucous carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	8	7	15
8083: Basaloid squamous cell carcinoma	1	0	1
8090: Basal cell carcinoma, NOS	1	0	1
8094: Basosquamous carcinoma	1	0	1
8097: Basal cell carcinoma, nodular	1	0	1
8098: Adenoid basal carcinoma	0	1	1
8720: Malignant melanoma, NOS	7	7	14
8721: Nodular melanoma	2	0	2
8743: Superficial spreading melanoma	0	1	1
8832: Dermatofibrosarcoma, NOS	4	0	4
C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES	12	14	26
8800: Sarcoma, NOS	1	2	3
8801: Spindle cell sarcoma	1	0	1
8802: Giant cell sarcoma	3	2	5
8802: Pleomorphic cell sarcoma	1	0	1
8811: Fibromyxosarcoma	0	2	2
8850: Liposarcoma, NOS	0	1	1
8851: Liposarcoma, well differentiated	1	0	1
8852: Myxoid liposarcoma	0	1	1
8854: Pleomorphic liposarcoma	0	1	1
8890: Leiomyosarcoma, NOS	2	2	4
8901: Pleomorphic rhabdomyosarcoma, adult type	0	1	1
9044: Clear cell sarcoma, NOS	0	1	1
9120: Hemangiosarcoma	1	0	1
9220: Chondrosarcoma, NOS	1	0	1
9540: Malignant peripheral nerve sheath tumor	1	0	1
9581: Alveolar soft part sarcoma	0	1	1

PATHOLOGY AND SITES	Male	Female	Total
C50 BREAST	1	761	762
8000: No histological proof	0	8	8
8010: Carcinoma, NOS	0	6	6
8022: Pleomorphic carcinoma	0	1	1
8050: Papillary carcinoma, NOS	0	4	4
8140: Adenocarcinoma, NOS	0	1	1
8480: Mucinous adenocarcinoma	0	7	7
8500: Invasive ductal carcinoma, NOS	1	706	707
8504: Intracystic carcinoma, NOS	0	1	1
8510: Medullary carcinoma, NOS	0	2	2
8520: Lobular carcinoma, NOS	0	14	14
8522: Infiltrating duct and lobular carcinoma	0	3	3
8523: Infiltrating duct mixed with other types of carcinoma (C50.9)	0	3	3
8575: Metaplastic carcinoma, NOS	0	3	3
9020: Phyllodes tumor, malignant	0	2	2
C51 VULVA	0	9	9
8010: Carcinoma, NOS	0	1	1
8070: Squamous cell carcinoma, NOS	0	6	6
8140: Adenocarcinoma, NOS	0	1	1
8542: Paget disease, extramammary	0	1	1
C52 VAGINA	0	2	2
8070: Squamous cell carcinoma, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	1	1
C53 CERVIX UTERI	0	211	211
8000: No histological proof	0	5	5
8010: Carcinoma, NOS	0	5	5
8041: Small cell neuroendocrine carcinoma	0	3	3
8052: Papillary squamous cell carcinoma	0	1	1
8070: Squamous cell carcinoma, NOS	0	145	145
8071: Squamous cell carcinoma, keratinizing, NOS	0	3	3
8072: Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	2	2
8076: Squamous cell carcinoma, micro-invasive	0	1	1
8140: Adenocarcinoma, NOS	0	26	26
8380: Endometrioid carcinoma	0	3	3
8384: Adenocarcinoma, endocervical type	0	5	5
8480: Mucinous adenocarcinoma	0	2	2
8490: Mucinous carcinoma, signet-ring cell type	0	1	1
8560: Adenosquamous carcinoma	0	7	7
8720: Malignant melanoma, NOS	0	1	1
8900: Rhabdomyosarcoma	0	1	1
C54 CORPUS UTERI	0	66	66
8020: Carcinoma, undifferentiated type, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	2	2
8380: Endometrioid carcinoma	0	53	53
8441: Serous carcinoma	0	4	4
8931: Endometrial stromal sarcoma, low grade	0	1	1
8980: Carcinosarcoma, NOS	0	5	5

PATHOLOGY AND SITES	Male	Female	Total
C56 OVARY	0	12	12
8000: No histological proof	0	4	4
8010: Carcinoma, NOS	0	1	1
8140: Adenocarcinoma, NOS	0	1	1
8310: Clear cell adenocarcinoma, NOS	0	3	3
8380: Endometrioid carcinoma	0	1	1
8441: Serous carcinoma	0	2	2
C60 PENIS	7	0	7
8070: Squamous cell carcinoma, NOS	7	0	7
C61 PROSTATE GLAND	185	0	185
8000: No histological proof	3	0	3
8010: Carcinoma, NOS	1	0	1
8140: Adenocarcinoma, NOS	146	0	146
8550: Acinar cell carcinoma	34	0	34
8551: Acinar cell cystadenocarcinoma	1	0	1
C64 KIDNEY	6	4	10
8120: Transitional cell carcinoma, NOS	2	1	3
8130: Papillary transitional cell carcinoma	1	0	1
8140: Adenocarcinoma, NOS	1	0	1
8312: Renal cell carcinoma	2	3	5
C65 RENAL PELVIS	0	1	1
8000: No histological proof	0	1	1
C66 Ureter	0	1	1
8130: Papillary transitional cell carcinoma	0	1	1
C67 BLADDER	24	3	27
8041: Small cell neuroendocrine carcinoma	1	0	1
8120: Transitional cell carcinoma, NOS	20	2	22
8130: Papillary transitional cell carcinoma (C67.9)	3	1	4
C71 BRAIN	12	9	21
9370: Chordoma, NOS	1	0	1
9380: Glioma, malignant	1	2	3
9382: Anaplastic oligoastrocytoma	1	0	1
9391: Ependymoma, NOS	0	1	1
9400: Astrocytoma, NOS	3	1	4
9401: Astrocytoma, anaplastic	2	0	2
9440: Glioblastoma, NOS	4	4	8
9450: Oligodendroglioma	0	1	1
C73 THYROID GLAND	23	97	120
8010: Carcinoma, NOS	0	1	1
8260: Papillary adenocarcinoma, NOS	16	59	75
8290: Oxyphilic adenocarcinoma	1	3	4
8330: Follicular adenocarcinoma, NOS	1	4	5
8335: Follicular carcinoma, minimally invasive	1	5	6
8340: Papillary carcinoma, follicular variant	4	23	27
8341: Papillary microcarcinoma	0	2	2

PATHOLOGY AND SITES	Male	Female	Total
C74 ADRENAL GLAND	0	1	1
8700: Pheochromocytoma, malignant	0	1	1
C77 LYMPH NODES	43	30	73
9590: Malignant lymphoma, NOS	0	1	1
9591: Malignant lymphoma, non-Hodgkin	3	3	6
9596: Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
9650: Hodgkin lymphoma, NOS	1	1	2
9651: Hodgkin lymphoma, lymphocyte-rich	1	0	1
9652: Hodgkin lymphoma, mixed cellularity, NOS	1	1	2
9671: Malignant lymphoma, lymphoplasmacytic	0	1	1
9680: Malignant lymphoma, large B-cell, diffuse, NOS	27	18	45
9690: Follicular lymphoma, NOS	1	0	1
9699: Marginal zone B-cell lymphoma, NOS	2	2	4
9708: Subcutaneous panniculitis like T-cell lymphoma	0	1	1
9714: Anaplastic large cell lymphoma, T-cell and Null cell type	0	1	1
9719: NK/T-cell lymphoma, nasal and nasal-type	4	0	4
9729: Precursor T-cell lymphoblastic lymphoma	0	1	1
9735: Plasmablastic lymphoma	2	0	2
C80 UNKNOWN PRIMARY SITE	10	15	25
8000: No histological proof	7	6	13
8010: Carcinoma, NOS	0	2	2
8041: Small cell carcinoma, NOS	1	0	1
8070: Squamous cell carcinoma, NOS	1	2	3
8140: Adenocarcinoma, NOS	1	5	6

Publications of cancer registry, Lampang Cancer Hospital

Hospital-based Cancer Registration Publications:

- Hospital Based Cancer Registry, LPCH 1999 (Published April 2002)
- Hospital Based Cancer Registry, LPCH 2001 (Published June 2002)
- Hospital Based Cancer Registry, LPCH 2002 (Published April 2003)
- Hospital Based Cancer Registry, LPCH 2003 (Published June 2004)
- Hospital Based Cancer Registry, LPCH 2004 (Published June 2005)
- Hospital Based Cancer Registry, LPCH 2005 (Published June 2006)
- Hospital Based Cancer Registry, LPCH 2006 (Published March 2007)
- Hospital Based Cancer Registry, LPCH 2007 (Published July 2008)
- Hospital Based Cancer Registry, LPCH 2008 (Published August 2009)
- Hospital Based Cancer Registry, LPCH 2009 (Published August 2010)
- Hospital Based Cancer Registry, LPCH 2010 (Published August 2011)
- Hospital Based Cancer Registry, LPCH 2011 (Published March 2012)
- Hospital Based Cancer Registry, LPCH 2012 (Published March 2013)
- Hospital Based Cancer Registry, LPCH 2013 (Published February 2014)
- Hospital Based Cancer Registry, LPCH 2014 (Published June 2015)
- Hospital Based Cancer Registry, LPCH 2015 (Published June 2016)
- Hospital Based Cancer Registry, LPCH 2016 (Published June 2017)
- Hospital Based Cancer Registry, LPCH 2017 (Published June 2018)
- Hospital Based Cancer Registry, LPCH 2018 (Published June 2019)
- Hospital Based Cancer Registry, LPCH 2019 (Published May 2020)
- Hospital Based Cancer Registry, LPCH 2020 (Published May 2021)
- Hospital Based Cancer Registry, LPCH 2021 (Published June 2022)

Population- based Cancer Registration Publications:

- Cancer Incidence in Lampang Vol. II, 1993-1997 (Published January 2002)
- Cancer Mortality in Lampang, 1990-2000 (Published August 2003)
- Cancer Incidence and Mortality in Lampang Vol. III, 1998-2002 (Published July 2004)
- Cancer Survival in Lampang, 1990-2002 (Published November 2005)
- Cancer Incidence in Lamphun, 1998-2002 (Published May 2006)
- Cancer Incidence in Phitsanulok, 1998-2002 (Published September 2006)
- Trends in Cancer Incidence in Lampang, Thailand, 1985-2004 (Published October 2007)
- Cancer Incidence in Northern, Thailand, 2003-2007 (Published October 2009)
- Cancer incidence in Phare, Thailand, 2007-2009 (Published August 2011)
- Trend cancer survival in Lampang, Thailand, 1988-2007 (Published September 2012)
- Cancer incidence in Chiang Rai, Thailand, 2008-2010 (Published October 2013)
- Cancer Incidence in Northern, Thailand, 2008-2012 (Published October 2014)
- Cancer Incidence Trend in Lampang, Thailand, 1988-2012 (Published November 2014)
- Cancer Incidence Trend in Phayao, Thailand, 2010-2012 (Published September 2015)
- Cancer Incidence Trend in Northern Thailand, 1993-2012 (Published December 2015)
- Cancer Survival in Northern Thailand, 2003-2012 (Published August 2016)
- Epidemiology of Liver Cancer in North Thailand (Published September 2017)
- Trends In Cancer Incidence and Mortality in Northern Thailand, 1993-2017 (Published February 2020)
- Cancer epidemiology of an aging population in Upper-Northern Thailand from 2013 to 2017 (Journal of Medicine and Health Sciences Published Vol.28 No.2 August 2021)

Cancer in Thailand Publications:

- Cancer in Thailand vol. II, 1992-1994 (Published 1999)
- Cancer in Thailand vol. III, 1995-1997 (Published 2003)
- Cancer in Thailand vol. IV, 1998-2000 (Published 2007)
- Cancer in Thailand vol. V, 2001-2003 (Published 2009)
- Cancer in Thailand vol. VI, 2004-2006 (Published 2012)
- Cancer in Thailand vol. VII, 2007-2009 (Published 2013)
- Cancer in Thailand vol. VIII, 2010-2012 (Published 2015)
- Cancer in Thailand vol. IX, 2013-2015 (Published 2018)
- Cancer in Thailand vol. X, 2016-2018 (Published 2021)

International Publications:

- Cancer in Five Continents Vol. VIII, 1993-1997 IARC, WHO. Scientific Publications No. 155 (Published 2002)
- Cancer in Five Continents Vol. IX, 1998-2002 IARC, WHO Scientific Publications No. 160 (Published 2007)
- Cancer in Five Continents Vol. X, 2003-2007 IARC, WHO Scientific Publications No. 164 (Published 2013)
- Cancer Survival in Africa, Asia, the Caribbean and Central America, IARC, WHO Scientific Publications No. 162 (Published 2011)
- Lalitwongsa S, Pongnikorn D, Daoprasert K, Sriplung H, Bilheem S. Breast Cancer in Lampang, a Province in Northern Thailand: Analysis of 1993-2012 Incidence Data and Future Trends. *Asian Pac J Cancer Prev*. 2015;16(18):8327-33.
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015 Mar 14;385(9972):977-1010.
- Pruksakorn D, Phanphaisarn A, Pongnikorn D, Daoprasert K, Teeyakasem P, Chaiyawat P, et al. AgeStandardized Incidence Rates and Survival of Osteosarcoma in Northern Thailand. *Asian Pac J Cancer Prev*. 2016;17(7):3455-8.
- Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, CONCORD working group, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):405-13.
- Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, CONCORD working group, et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol*. 2017 Feb;144(2):396-404.
- Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol*. 2017 Jun;18(6):719-31.
- Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, CONCORD working group, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. *Lancet Haematol*. 2017;4(5):e202-17.
- Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens. *Cancers (Basel)* [Internet]. 2017 Aug 17;9(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575611/>

- Sripan P, Sriplung H, Pongnikorn D, Virani S, Bilheem S, Chaisaengkhaum U, et al. Trends in Female Breast Cancer by Age Group in the Chiang Mai Population. *Asian Pac J Cancer Prev*. 2017 01;18(5):1411–6.
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, CONCORD working group, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018 Jan 30;
- Pongnikorn D, Daoprasert K, Waisri N, Laversanne M, Bray F. Cancer incidence in northern Thailand: Results from six population-based cancer registries 1993-2012. *Int J Cancer*. 2018 May 1;142(9):1767–75.
- Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, CONCORD Working Group*. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. www.thelancet.com Published online January 30, 2018
- Joanne T. Chang, Jihyoun Jeon, Hutcha Sriplung, Seesai Yeesoonsang, Surichai Bilheem, Laura Rozek, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Patravoot Vatanasapt, Krittika Suwanrungruang, Rafael Meza. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. *American Society of Clinical Oncology*, 2018
- Ilona Argirion, Katie R Zarins, Kali Defever, Krittika Suwanrungruang, Joanne T Chang, Donsuk Pongnikorn, Imjai Chitapanarux, Hutcha Sriplung, Patravoot Vatanasapt, Laura S Rozek. Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region. *Journal of global oncology*. 2019;5.
- Serena S Bidwell, Catherine C Peterson, Kathryn Demanelis, Katie R Zarins, Rafael Meza, Hutcha Sriplung, Surapon Wiangnon, Thirachit Chotsampancharoen, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Krittika Suwanrungruang, Wasan Chansaard, Laura S Rozek. Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011. *Pediatric blood & cancer*. 2019;66(1).

- Donlapark Ponnoprat, Papangkorn Inkeaw, Jeerayut Chaijaruwanich, Patrinee Traisathit, Patumrat Sripan, Nakarin Inmutto, Wittanee Na Chiangmai, Donsuk Pongnikorn, Imjai Chitapanarux. Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans. Medical & biological engineering & computing. 2020;58(10).
- Donsuk Pongnikorn, Phichayut Phinyo, Jayanton Patumanond, Karnchana Daoprasert, Pachaya Phothong, Boonying Siribumrungwong. Individualized Prediction of Breast Cancer Survival Using Flexible Parametric Survival Modeling: Analysis of a Hospital-Based National Clinical Cancer Registry. Cancers. 2021;13(7).
- Jeerawan Klangjorhor, Donsuk Pongnikorn, Areerak Phanphaisarn, Parunya Chaiyawat, Pimpisa Teeyakasem, Pathacha Suksakit, Arnat Pasena, Sasimol Udomruk, Santhasiri Orrapin, Samatit Pornwattanavate, Narate Waisri, Karnchana Daoprasert, Taweechok Wisanuyotin, Chalongpon Santong, Suleeporn Sangrajang, et al. An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001–2015. Cancer Epidemiology. 2022;76.



Reference

**LPCH Cancer Registry. Hospital Based Cancer Registry, Lampung Cancer Hospital 2022.
Lampung: Lampung Cancer Hospital, 2023.**





สถิติโรคมะเร็ง โรงพยาบาลมะเร็งลำปาง ปี พ.ศ. 2565 Hospital-Based Cancer Registry 2022



Publisher

Lampang Cancer Hospital, Department of Medical Services,
Ministry of Public Health

199, Village 12, Pichai Sub-district, Muang district, Lampang, 52000